0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
In This Issue of Archives of Internal Medicine |

In This Issue of Archives of Internal Medicine FREE

Arch Intern Med. 2001;161(20):2405. doi:10.1001/archinte.161.20.2405.
Text Size: A A A
Published online

ASSOCIATION OF MUTATIONS IN THE HEMOCHROMATOSIS GENE WITH SHORTER LIFE EXPECTANCY

Bathum and colleages investigated whether the frequency of carriers for hereditary hemochromatosis changes as a function of age. Genotyping for the C282Y mutation in the HFE gene (the mutation most often associated with hereditary hemochromatosis) was performed in 1784 subjects aged 45 to 100 years, and a trend toward fewer heterozygotes with age was found. The trend was statistically significant for the whole population and for women, but not for men. This age-related reduction suggests that carrier status is associated with shorter life expectancy.

See Article

GENETIC ANALYSIS AS A VALUABLE KEY TO DIAGNOSIS AND TREATMENT OF PERIODIC FEVER

In this case report, Simon et al demonstrate the importance of adequately examining family history in a patient with unexplained periodic fever episodes. In the 2 cases described, subsequent genetic analysis of the gene for the tumor necrosis factor (TNF) receptor led to a diagnosis of TNF receptor–associated periodic syndrome (TRAPS), an autosomal dominantly inherited disorder characterized by episodes of fever, arthralgia, and skin lesions. Elucidation of the molecular background has facilitated the treatment of TRAPS because blocking of TNF signaling seems to alleviate the symptoms.

See Article

MTDNA DISEASE IN THE PRIMARY CARE SETTING

Mitochondrial DNA (mtDNA) mutations are surprisingly common, with a prevalence of up to 10% in patients with diabetes mellitus, hearing loss, or renal failure. A 36-year-old man with a history of psychosis, seizures, sensorineural hearing loss, and a family history of diabetes mellitus and heart disease had undergone evaluation by primary care physicians for 15 years without a unifying diagnosis. Physiologic, biochemical, and genetic testing established the diagnosis of mitochondrial encephalopathy, lactic acidosis, and stroke-like syndrome. Diagnosing mtDNA disorders requires a careful integration of clinical signs and symptoms with pedigree analysis and multidisciplinary testing. Diagnosis is important to provide genetic counseling, avoid unnecessary evaluation, and facilitate therapy for symptomatic relief.

See Article

GENOTYPE AND PHENOTYPE ANALYSIS OF 171 PATIENTS REFERRED FOR MOLECULAR STUDY OF THE FIBRILLIN-1 GENE FBN1 BECAUSE OF SUSPECTED MARFAN SYNDROME

In this study, the clinical and molecular data were reviewed for 171 consecutive patients referred for FBN1 analysis because of a diagnosis of Marfan syndrome (MFS) or signs suggestive of MFS. A diagnosis of MFS based on the Ghent criteria was highly correlated with an FBN1 mutation (66%). Fifty percent of children with "emerging" MFS had mutations, whereas only 5% of patients with Marfan-related conditions had mutations. These data show first that a comprehensive clinical evaluation is mandatory before establishing a definitive diagnosis and second, that FBN1 mutation analysis may be helpful, particularly in families displaying phenotypic variability or to identify children at risk for MFS who need careful clinical follow-up.

See Article

HEREDITARY ANGIOEDEMA: A BROAD REVIEW FOR CLINICIANS

Hereditary angioedema (HAE) is an autosomal dominant disease that afflicts l in 10 000 to 1 in 150 000 persons. It is an uncommon condition that may present with rather common symptoms and may be misdiagnosed in certain circumstances. Hereditary angioedema manifests as recurrent attacks of intense, massive, localized edema without concomitant pruritus. Skin, as well as visceral organs, may be involved by the typically massive local edema. Involvement of the upper airways may result in severe life-threatening symptoms, including the risk of asphyxiation, unless appropriate interventions are taken. Historically, 2 types of HAE have been described; however, a variant, possibly X-linked, inherited angioedema has recently been described and tentatively named "type 3" HAE. Clinicians should keep this group of disorders in their differential diagnosis of unexplained episodic cutaneous angioedema or unexplained abdominal pain.

Place holder to copy figure label and caption

HMWK indicates high-molecular-weight kininogen; MAC, membrane attack complex.

Graphic Jump Location

See Article

Figures

Place holder to copy figure label and caption

HMWK indicates high-molecular-weight kininogen; MAC, membrane attack complex.

Graphic Jump Location

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.